207 related articles for article (PubMed ID: 27126828)
1. Specialty pharmacy services for patients receiving oral medications for solid tumors.
Stein J; Mann J
Am J Health Syst Pharm; 2016 Jun; 73(11):775-96. PubMed ID: 27126828
[TBL] [Abstract][Full Text] [Related]
2. Specialty pharmacy for hematologic malignancies.
Fajardo S; Zook F; Dotson E
Am J Health Syst Pharm; 2016 Jun; 73(11):797-809. PubMed ID: 27126835
[TBL] [Abstract][Full Text] [Related]
3. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
4. Utilization patterns for oral oncology medications in a specialty pharmacy cycle management program.
Deutsch S; Koerner P; Miller RT; Craft Z; Fancher K
J Oncol Pharm Pract; 2016 Feb; 22(1):68-75. PubMed ID: 25301744
[TBL] [Abstract][Full Text] [Related]
5. Oral Targeted Therapies and Central Nervous System (CNS) Metastases.
Gabay MP; Wirth SM; Stachnik JM; Overley CL; Long KE; Bressler LR; Villano JL
CNS Drugs; 2015 Nov; 29(11):935-52. PubMed ID: 26563196
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacotherapy of solid tumors. New hopes and frustrations].
Grünwald V; Rickmann M
Internist (Berl); 2014 Oct; 55(10):1220-7. PubMed ID: 25139705
[TBL] [Abstract][Full Text] [Related]
7. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
Daud A; Tsai K
Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
[TBL] [Abstract][Full Text] [Related]
8. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).
Launay-Vacher V; Aapro M; De Castro G; Cohen E; Deray G; Dooley M; Humphreys B; Lichtman S; Rey J; Scotté F; Wildiers H; Sprangers B
Ann Oncol; 2015 Aug; 26(8):1677-84. PubMed ID: 25735315
[TBL] [Abstract][Full Text] [Related]
9. Impact of an integrated oral chemotherapy program on patient adherence.
Morgan KP; Muluneh B; Deal AM; Amerine LB
J Oncol Pharm Pract; 2018 Jul; 24(5):332-336. PubMed ID: 28379068
[TBL] [Abstract][Full Text] [Related]
10. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
11. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
[TBL] [Abstract][Full Text] [Related]
12. MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.
Pietrantonio F; Oddo D; Gloghini A; Valtorta E; Berenato R; Barault L; Caporale M; Busico A; Morano F; Gualeni AV; Alessi A; Siravegna G; Perrone F; Di Bartolomeo M; Bardelli A; de Braud F; Di Nicolantonio F
Cancer Discov; 2016 Sep; 6(9):963-71. PubMed ID: 27325282
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous Complications of Targeted Melanoma Therapy.
de Golian E; Kwong BY; Swetter SM; Pugliese SB
Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
15. Targeting the human kinome for cancer therapy.
Daly RJ
Crit Rev Oncog; 2012; 17(1):vi-vii. PubMed ID: 22471667
[No Abstract] [Full Text] [Related]
16. Building an outpatient cancer center pharmacy program across a tristate region.
Skledar SJ; Doedyns A; Yourich B
Am J Health Syst Pharm; 2015 Jan; 72(2):126-32. PubMed ID: 25550136
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors.
Ruiz-Camps I; Aguilar-Company J
Infect Dis Clin North Am; 2020 Jun; 34(2):257-270. PubMed ID: 32334988
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
[TBL] [Abstract][Full Text] [Related]
19. Impact of a specialty pharmacy case management service on adherence in patients receiving oral antineoplastic agents.
Middendorff G; Elsey R; Lounsbery B; Chadwell R
J Oncol Pharm Pract; 2018 Jul; 24(5):371-378. PubMed ID: 28509613
[TBL] [Abstract][Full Text] [Related]
20. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.
Engle JA; Kolesar JM
Am J Health Syst Pharm; 2014 Nov; 71(22):1933-8. PubMed ID: 25349236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
